Altered arsenic disposition in experimental nonalcoholic fatty liver disease

Mark J. Canet, Rhiannon N. Hardwick, April D. Lake, Michael J. Kopplin, George L. Scheffer, Walter Klimecki, A Jay Gandolfi, Nathan J Cherrington

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is represented by a spectrum of liver pathologies ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Liver damage sustained in the progressive stages of NAFLD may alter the ability of the liver to properly metabolize and eliminate xenobiotics. The purpose of the current study was to determine whether NAFLD alters the disposition of the environmental toxicant arsenic. C57BL/6 mice were fed either a high-fat or a methionine-choline-deficient diet to model simple steatosis and NASH, respectively. At the conclusion of the dietary regimen, all mice were given a single oral dose of either sodium arsenate or arsenic trioxide. Mice with NASH excreted significantly higher levels of total arsenic in urine (24 h) compared with controls. Total arsenic in the liver and kidneys of NASH mice was not altered; however, NASH liver retained significantly higher levels of the monomethyl arsenic metabolite, whereas dimethyl arsenic was retained significantly less in the kidneys of NASH mice. NASH mice had significantly higher levels of the more toxic trivalent form in their urine, whereas the pentavalent form was preferentially retained in the liver of NASH mice. Moreover, hepatic protein expression of the arsenic biotransformation enzyme arsenic (3+ oxidation state) methyltransferase was not altered in NASH animals, whereas protein expression of the membrane transporter multidrug resistance-associated protein 1 was increased, implicating cellular transport rather than biotransformation as a possible mechanism. These results suggest that NASH alters the disposition of arsenical species, which may have significant implications on the overall toxicity associated with arsenic in NASH.

Original languageEnglish (US)
Pages (from-to)1817-1824
Number of pages8
JournalDrug Metabolism and Disposition
Volume40
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Arsenic
Liver
Biotransformation
Non-alcoholic Fatty Liver Disease
Urine
Arsenicals
Kidney
Membrane Transport Proteins
Poisons
Methyltransferases
Xenobiotics
Choline
Inbred C57BL Mouse
Methionine
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Altered arsenic disposition in experimental nonalcoholic fatty liver disease. / Canet, Mark J.; Hardwick, Rhiannon N.; Lake, April D.; Kopplin, Michael J.; Scheffer, George L.; Klimecki, Walter; Gandolfi, A Jay; Cherrington, Nathan J.

In: Drug Metabolism and Disposition, Vol. 40, No. 9, 09.2012, p. 1817-1824.

Research output: Contribution to journalArticle

Canet, Mark J. ; Hardwick, Rhiannon N. ; Lake, April D. ; Kopplin, Michael J. ; Scheffer, George L. ; Klimecki, Walter ; Gandolfi, A Jay ; Cherrington, Nathan J. / Altered arsenic disposition in experimental nonalcoholic fatty liver disease. In: Drug Metabolism and Disposition. 2012 ; Vol. 40, No. 9. pp. 1817-1824.
@article{39a3818ecb1c4410a1f82666d395b4c6,
title = "Altered arsenic disposition in experimental nonalcoholic fatty liver disease",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is represented by a spectrum of liver pathologies ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Liver damage sustained in the progressive stages of NAFLD may alter the ability of the liver to properly metabolize and eliminate xenobiotics. The purpose of the current study was to determine whether NAFLD alters the disposition of the environmental toxicant arsenic. C57BL/6 mice were fed either a high-fat or a methionine-choline-deficient diet to model simple steatosis and NASH, respectively. At the conclusion of the dietary regimen, all mice were given a single oral dose of either sodium arsenate or arsenic trioxide. Mice with NASH excreted significantly higher levels of total arsenic in urine (24 h) compared with controls. Total arsenic in the liver and kidneys of NASH mice was not altered; however, NASH liver retained significantly higher levels of the monomethyl arsenic metabolite, whereas dimethyl arsenic was retained significantly less in the kidneys of NASH mice. NASH mice had significantly higher levels of the more toxic trivalent form in their urine, whereas the pentavalent form was preferentially retained in the liver of NASH mice. Moreover, hepatic protein expression of the arsenic biotransformation enzyme arsenic (3+ oxidation state) methyltransferase was not altered in NASH animals, whereas protein expression of the membrane transporter multidrug resistance-associated protein 1 was increased, implicating cellular transport rather than biotransformation as a possible mechanism. These results suggest that NASH alters the disposition of arsenical species, which may have significant implications on the overall toxicity associated with arsenic in NASH.",
author = "Canet, {Mark J.} and Hardwick, {Rhiannon N.} and Lake, {April D.} and Kopplin, {Michael J.} and Scheffer, {George L.} and Walter Klimecki and Gandolfi, {A Jay} and Cherrington, {Nathan J}",
year = "2012",
month = "9",
doi = "10.1124/dmd.112.046177",
language = "English (US)",
volume = "40",
pages = "1817--1824",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "9",

}

TY - JOUR

T1 - Altered arsenic disposition in experimental nonalcoholic fatty liver disease

AU - Canet, Mark J.

AU - Hardwick, Rhiannon N.

AU - Lake, April D.

AU - Kopplin, Michael J.

AU - Scheffer, George L.

AU - Klimecki, Walter

AU - Gandolfi, A Jay

AU - Cherrington, Nathan J

PY - 2012/9

Y1 - 2012/9

N2 - Nonalcoholic fatty liver disease (NAFLD) is represented by a spectrum of liver pathologies ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Liver damage sustained in the progressive stages of NAFLD may alter the ability of the liver to properly metabolize and eliminate xenobiotics. The purpose of the current study was to determine whether NAFLD alters the disposition of the environmental toxicant arsenic. C57BL/6 mice were fed either a high-fat or a methionine-choline-deficient diet to model simple steatosis and NASH, respectively. At the conclusion of the dietary regimen, all mice were given a single oral dose of either sodium arsenate or arsenic trioxide. Mice with NASH excreted significantly higher levels of total arsenic in urine (24 h) compared with controls. Total arsenic in the liver and kidneys of NASH mice was not altered; however, NASH liver retained significantly higher levels of the monomethyl arsenic metabolite, whereas dimethyl arsenic was retained significantly less in the kidneys of NASH mice. NASH mice had significantly higher levels of the more toxic trivalent form in their urine, whereas the pentavalent form was preferentially retained in the liver of NASH mice. Moreover, hepatic protein expression of the arsenic biotransformation enzyme arsenic (3+ oxidation state) methyltransferase was not altered in NASH animals, whereas protein expression of the membrane transporter multidrug resistance-associated protein 1 was increased, implicating cellular transport rather than biotransformation as a possible mechanism. These results suggest that NASH alters the disposition of arsenical species, which may have significant implications on the overall toxicity associated with arsenic in NASH.

AB - Nonalcoholic fatty liver disease (NAFLD) is represented by a spectrum of liver pathologies ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Liver damage sustained in the progressive stages of NAFLD may alter the ability of the liver to properly metabolize and eliminate xenobiotics. The purpose of the current study was to determine whether NAFLD alters the disposition of the environmental toxicant arsenic. C57BL/6 mice were fed either a high-fat or a methionine-choline-deficient diet to model simple steatosis and NASH, respectively. At the conclusion of the dietary regimen, all mice were given a single oral dose of either sodium arsenate or arsenic trioxide. Mice with NASH excreted significantly higher levels of total arsenic in urine (24 h) compared with controls. Total arsenic in the liver and kidneys of NASH mice was not altered; however, NASH liver retained significantly higher levels of the monomethyl arsenic metabolite, whereas dimethyl arsenic was retained significantly less in the kidneys of NASH mice. NASH mice had significantly higher levels of the more toxic trivalent form in their urine, whereas the pentavalent form was preferentially retained in the liver of NASH mice. Moreover, hepatic protein expression of the arsenic biotransformation enzyme arsenic (3+ oxidation state) methyltransferase was not altered in NASH animals, whereas protein expression of the membrane transporter multidrug resistance-associated protein 1 was increased, implicating cellular transport rather than biotransformation as a possible mechanism. These results suggest that NASH alters the disposition of arsenical species, which may have significant implications on the overall toxicity associated with arsenic in NASH.

UR - http://www.scopus.com/inward/record.url?scp=84865182093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865182093&partnerID=8YFLogxK

U2 - 10.1124/dmd.112.046177

DO - 10.1124/dmd.112.046177

M3 - Article

C2 - 22699396

AN - SCOPUS:84865182093

VL - 40

SP - 1817

EP - 1824

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 9

ER -